Director of the Center. Gamalei Alexander GintsburgMOSCOW, January 16The nasal vaccine against coronavirus, which the Gamaleya Research Center for Epidemiology and Microbiology is working on, will be two-component, but if it is used as a booster, then one component is enough, the director of the center told RIA Novosti Alexander Gunzburg.
"Nasal vaccine — two-component. If primary vaccination, then two components are used, and if as a booster, then one component", he said.
Earlier, Denis Logunov, deputy head of the Gamaleya center, said that the Sputnik V nasal vaccine against COVID-19 is painless , has a minimum of side effects, will create an additional barrier in the form of immunity in the upper respiratory tract. In early November, Gunzburg reported that an additional nasal vaccine vaccinated against COVID-19 would not carry the virus.
Gamaleya Center: Sputnik nasal is effective against omicron strain The Gamaleya Center has already developed several vaccines for the prevention of COVID-19: Sputnik V, which has shown high efficiency and safety and has already received approval in more than 70 countries, Sputnik Light, intended primarily for revaccination, and «Sputnik M» — for adolescents. In addition, Russia uses «EpiVakKorona», created in the Novosibirsk center «Vector», and «KoviVak», developed by the Chumakov Center of the Russian Academy of Sciences. Vaccination remains the most reliable way to protect from coronavirus. According to the head of the Russian Ministry of Health Mikhail Murashko, the proportion of those vaccinated among those infected with COVID-19 does not exceed four percent, severe cases are few, while the vast majority of patients in hospitals are unvaccinated. At the end of September, the WHO announced the connection between mortality from SARS-CoV-2 and the refusal of preventive immunization. with revaccination